GSK plc (GLAXF)
| Market Cap | 98.09B |
| Revenue (ttm) | 43.24B |
| Net Income (ttm) | 7.39B |
| Shares Out | n/a |
| EPS (ttm) | 1.79 |
| PE Ratio | 13.28 |
| Forward PE | 10.02 |
| Dividend | 0.84 (3.69%) |
| Ex-Dividend Date | Nov 13, 2025 |
| Volume | 200 |
| Average Volume | 3,455 |
| Open | 23.98 |
| Previous Close | 22.79 |
| Day's Range | 23.98 - 23.98 |
| 52-Week Range | 15.54 - 25.00 |
| Beta | 0.23 |
| RSI | 54.97 |
| Earnings Date | Feb 4, 2026 |
About GSK plc
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It a... [Read more]
Financial Performance
In 2024, GSK plc's revenue was 31.38 billion, an increase of 3.46% compared to the previous year's 30.33 billion. Earnings were 2.58 billion, a decrease of -47.75%.
Financial numbers in GBP Financial StatementsNews
UK approves GSK's twice-yearly asthma drug
UK's health regulator on Monday approved GSK's twice-yearly drug for use as an add-on treatment for asthma in patients aged 12 and older, as well as for a chronic inflammatory sinus condition in adult...
GSK's Nucala for COPD and Depemokimab for Asthma Get CHMP Nod in EU
GSK gets CHMP backing for Nucala in COPD and depemokimab in asthma, setting up possible Europe approvals in 2026 for IL-5 therapies.
Dividend Income: Lanny's October 2025 Summary
In October, we (my wife and I) received a dividend income total of $3,948.78. Crushing it for an off-month – thanks to Vanguard (VOO) and Fidelity (FXAIX) for paying in October. We had quite a few div...
GSK: Depemokimab And Jemperli Lead Next Wave (Rating Upgrade)
GSK has been impressing me with strong revenue and EPS numbers for the eighth quarter in a row. Also, on December 12, depemokimab, GSK's anti-IL-5 antibody with 6-month dosing, received a positive EMA...
GSK's $4 Billion Asthma Drug Gets First-Ever Green Light in Europe
GSK's $4 Billion Asthma Drug Gets First-Ever Green Light in Europe
GSK Gets FDA Nod for Blujepa in Uncomplicated Urogenital Gonorrhea
GSK wins FDA approval for Blujepa, a new oral antibiotic treatment option for uncomplicated urogenital gonorrhea.
GSK Gains CHMP Recommendation for Nucala in COPD Treatment
GSK Gains CHMP Recommendation for Nucala in COPD Treatment
GSK's Depemokimab Receives CHMP Approval Recommendation for Asthma and CRSwNP
GSK's Depemokimab Receives CHMP Approval Recommendation for Asthma and CRSwNP
GSK gets EU regulator backing for expanded use of RSV vaccine
GSK said on Friday a panel of the European Medicines Agency had backed the use of its respiratory syncytial virus (RSV) vaccine, Arexvy, for all adults above the age of 18, paving the way for broader ...
European health regulator recommends approval for GSK's twice yearly asthma drug
The European Medicines Agency has recommended the approval of GSK's add-on drug to treat asthma and a chronic inflammatory sinus condition, the company said on Friday.
GSK (GSK) Receives EMA Panel Endorsement for Expanded Arexvy Vaccine Use
GSK (GSK) Receives EMA Panel Endorsement for Expanded Arexvy Vaccine Use
GSK gets EU backing to market Arexvy RSV shot for all adults
GSK (GSK) Awaits EMA Decision on Expanded RSV Vaccine Use for Adults
GSK (GSK) Awaits EMA Decision on Expanded RSV Vaccine Use for Adults
GSK's Arexvy RSV Vaccine Recommended For Expanded Use In Adults 18+ By EMA Committee
(RTTNews) - GSK plc (GSK, GSK.L) announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the expansion of ...
FDA Expands Indication for GSK's Blujepa
FDA Expands Indication for GSK's Blujepa
GSK antibiotic Blujepa gains additional indication for gonorrhea
GSK’s Blujepa wins new FDA approval as a gonorrhea treatment in patients 12 years and up. REad more here.
GSK Gains FDA Approval for New Gonorrhea Antibiotic
GSK Gains FDA Approval for New Gonorrhea Antibiotic
The UK’s pharma deal was vital – but the GSK boss is right about US dominance
It would be absurd to claim the UK has suddenly become a life-sciences leader thanks to the new pricing and tariffs pact That’s gratitude, eh? It’s not even a fortnight since the government agreed to ...
US FDA approves GSK's oral treatment for gonorrhea
The U.S. Food and Drug Administration on Thursday approved GSK's oral treatment for gonorrhea, a sexually transmitted infection.
GSK's Risvutatug Rezetecan Gets FDA's Orphan Drug Tag in Lung Cancer
GSK gains FDA Orphan Drug Designation for risvutatug rezetecan, adding momentum to its fast-advancing solid-tumor pipeline.
GSK Stock Up Almost 19% in 3 Months: Should You Buy, Hold or Sell?
GSK's stock surge rides on strong Q3 results and raised guidance, as Specialty Medicines momentum offsets U.S. vaccine softness.
US is the best place for drugs companies to invest, says boss of London-based GSK
Emma Walmsley’s praise for US pharmaceutical market piles pressure on the UK government Business live – live updates The chief executive of GSK yesterday declared the US to be the best place for pharm...
UK pharma boss says US is the best country to invest in
In an interview with the BBC, Dame Emma Walmsley says she will not "shy away" from GSK's US expansion.
GSK's Antibody-Drug Conjugate Receives FDA Orphan Drug Designation
GSK's Antibody-Drug Conjugate Receives FDA Orphan Drug Designation
GSK: FDA Grants Orphan Drug Designation To GSK'227
(RTTNews) - GSK plc (GSK, GSK.L) announced that its B7-H3-targeted antibody-drug conjugate GSK'227, now referred to by its International Nonproprietary Name, risvutatug rezetecan, has received Orphan ...